Natera Stock Fair Value Calculator – Assenagon Asset Management S.A. Boosts Investment in Natera,, Signaling Confidence in Growth
July 4, 2023
☀️Trending News
Natera ($NASDAQ:NTRA), Inc. is a leading molecular diagnostics and genetic testing company that specializes in developing and commercializing non-invasive methods of testing for genetic disorders. Its products are used by clinical laboratories, hospitals, and other healthcare facilities around the world. Due to their growing confidence in the company’s future growth prospects, Assenagon Asset Management S.A. has decided to increase its stake in Natera, Inc. On June 29, 2023, Assenagon Asset Management S.A., a premier institutional investor, bolstered its holdings of Natera, Inc. shares. This move signals their confidence in Natera’s ability to continue to drive innovation and grow its business in the future.
Natera, Inc. has recently seen increased interest from investors due to its impressive track record of success in providing innovative solutions for non-invasive genetic testing and molecular diagnostics. The company is continuing to focus on introducing new technologies for providing more accurate results while also cutting costs for healthcare providers. With the continued support of Assenagon Asset Management S.A., Natera, Inc. is well-positioned to capitalize on the growing demand for its products and services over the coming years.
Market Price
This minor uptick comes in the wake of a major announcement that Assenagon Asset Management S.A. has increased their investment in NATERA, significantly strengthening the company’s position in the market. The boost to NATERA’s stock is a clear sign that Assenagon’s large-scale investment is a strong signal of confidence in the growth of the company. This could potentially signal a shift in the market sentiment towards the company, as more investors start to recognize its potential for success. With this newfound investment, NATERA is more well-equipped than ever to take advantage of potential opportunities and capitalize on its strengths. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 867.85 | -546.14 | -62.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -375.11 | 138.96 | 480.79 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.32k | 668.31 | 5.74 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 38.1% | – | -61.6% |
| FCF Margin | ROE | ROA |
| -48.2% | -49.3% | -25.3% |
Analysis – Natera Stock Fair Value Calculator
GoodWhale recently analyzed the fundamentals of NATERA, and we are pleased to share our findings. Our proprietary Valuation Line reveals that the intrinsic value of NATERA shares is around $89.4. However, the current market price stands at $48.8, which implies that it is undervalued by as much as 45.4%. This discrepancy between the intrinsic value and the stock price presents an incredibly lucrative opportunity to invest in NATERA. More…
Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
Natera Inc. has seen a rise in institutional investor confidence recently, as Assenagon Asset Management S.A. has recently increased their stake in the company. This is a positive sign that investors are confident in Natera’s future growth prospects. Analysts have noted that this could be a sign of improved earnings in the near future, as well as improved stock performance. With that in mind, Natera is an attractive investment opportunity for those looking to take advantage of its long-term growth potential.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
